Stryker Acquires Stanmore Implants

| Printer friendly version

Stryker Corporation recently announced the purchase of United Kingdom-based Stanmore Implants from SIW Holdings Limited for £35.6 million (about $52 million USD) in an all-cash transaction.  According to Stanmore’s website, it is a highly specialized organization, focusing on orthopaedic oncology and complex primary and revision cases in the upper limb, lower limb and pelvis.  Stryker notes that Stanmore has a significant focus on serving the needs of the orthopaedic oncology market, including making custom implants for adults and juveniles suffering from cancer.

David Floyd, group president of Stryker Orthopaedics, stated:

The acquisition of Stanmore Implants provides Stryker with differentiated technologies designed to provide the most effective solutions for orthopaedic oncology surgeons. This addition underscores Stryker’s commitment to our core joint replacement business and expands our presence in the global orthopaedic oncology market.

Stanmore’s online portfolio of products for adult patients includes modular implant solutions for the femur, tibia, knee, and humerus as well as oncology implants for the upper and lower limbs, and the pelvis. Stanmore’s portfolio also includes minimally-invasive prostheses for juvenile patients that can be adjusted, e.g., until the patient reaches full skeletal maturity, and what Stanmore calls its “non-invasive extendable implants” that are designed to be lengthened periodically by an external drive unit.

The purchase of Stanmore is the latest in a string of acquisitions for Stryker: in February, 2016, Stryker acquired Physio-Control International (in a $1.28 billion all-cash transaction); in February, 2016, Stryker agreed to acquire Synergetics’ neurology portfolio; in March, 2016 Stryker agreed to acquire Sage Products (in a $2.775 billion all-cash transaction); in April, 2016, Stryker acquired SafeWire’s minimally-invasive surgical portfolio; and in April, 2016, Stryker acquired CareFusion vertebral compression fracture (VCF) portfolio of products (in another all-cash transaction).

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.